In 2013, Mirna Therapeutics Inc. appointed Dr.Clay B. Siegall as one of its outside directors for its Board of Directors. Mirna Therapeutics said that they were very excited to have Dr.Siegall join their distinguished team, with his experience in the board pharmaceutical industry and achievements in the building of a successful oncology company. It is believed by Mirna Therapeutics that with the help of Dr. Siegall, they can continue to build and advance in the development of the microRNA-based therapeutics. MicroRNA-based therapeutics is known to be an exciting area when it comes to cancer research, and Mirna, with a strong pipeline is well-positioned with product candidates. Siegall said that he was pleased to join the board of directors for Mirna, as with early research in the miRNA field, he was looking forward to helping the team in advancing with promising programs that patients were in need of.
Siegall is the President, Co-founder, Chairman of the Board of directors, and Chief Executive Officer of Seattle Genetics.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Mirna Therapeutics is a biotechnology company who is focused on the commercialization and development of microRNA, as known as miRNA, therapeutics. Mirna Therapeutics has a foundational intellectual property portfolio for the therapeutic use of miRNAs, that have been developed by their own scientist, with in-licensed from other institutions as well. Mirna Therapeutics was founded in Austin Texas in 2007, and has received funding from both private investors and the state of texas.
Through the Leadership of Clay Siegall, Seattle Genetics has been able to build a diverse pipeline made up of antibody-based therapies that help in addressing the unmet medical needs for cancer patients. Seattle Genetics also has entered multiple strategic collaborations with leading pharmaceutical and biotechnology companies in oncology. Clay Siegall has had a hand in capital raising activities for Seattle Genetics, one of these activities included securing over 675 million dollars through private and public financing, this included the initial public offering for the company in 2001. Along with his time with Seattle Genetics, he has also worked with Alder BioPharmaceuticals, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute and National Institutes of Health. He is also an author, holding 15 patents and with over 70 publications.